Center-involved DME resolves faster with faricimab than aflibercept
October 2nd 2022The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
Donation bolsters Vanderbilt’s work in retinal vision research
October 1st 2022According to a Vanderbilt University news release, the International Retinal Research Foundation has extended a $10 million gift to establish a center dedicated to retinal vision research at the Vanderbilt Eye Institute and a directorship to support a physician-scientist leader in the Department of Ophthalmology and Visual Sciences.
EP. 2: EyeCon 2022: Location, location, location and bring the family
September 28th 2022The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.
Florida appeals court reinstates lawsuit against ophthalmologist
September 24th 2022The Florida Second District Court of Appeal has renewed a woman’s lawsuit claiming she suffered permanent eye damage when her ophthalmologist misdiagnosed her during nasal surgery. In its opinion, the appellate court ruled that the trial court erred when it dismissed the lawsuit.
EP. 1: EyeCon 2022: Nothing is better than in-person conferences
September 21st 2022Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.